GeneTether Therapeutics (XCNQ:GTTX) Change In Payables And Accrued Expense : C$-0.06 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is GeneTether Therapeutics Change In Payables And Accrued Expense?

GeneTether Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was C$0.02 Mil. It means GeneTether Therapeutics's Accounts Payable & Accrued Expense increased by C$0.02 Mil from Dec. 2023 to Mar. 2024 .

GeneTether Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was C$-0.07 Mil. It means GeneTether Therapeutics's Accounts Payable & Accrued Expense declined by C$0.07 Mil from Dec. 2022 to Dec. 2023 .

GeneTether Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for GeneTether Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneTether Therapeutics Change In Payables And Accrued Expense Chart

GeneTether Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

0.27

-0.17

-0.07

GeneTether Therapeutics Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial									0.02	-0.08	-0.01	0.01	0.02

GeneTether Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.06 Mil.

GeneTether Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of GeneTether Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

GeneTether Therapeutics (XCNQ:GTTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneTether Therapeutics Inc (XCNQ:GTTX) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, V1Y 2B3

Website

https://www.genetether.com

GeneTether Therapeutics Inc is a genetic medicines company focused on the development of high-efficiency precision gene editing for human therapeutics applications. It is engaged in creating gene-editing therapies based on the proprietary GeneTether platform. Further, it is focused on building a discovery pipeline for the treatment of rare, monogenic diseases of the kidney and the skin.

GeneTether Therapeutics (XCNQ:GTTX) Headlines

No Headlines